Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 30, 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial results report.
Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction.
Material Changes
The filing details an increase in the holding of Ordinary Shares by a connected person, Dr. S. Dexter, following the re-investment of a dividend paid on April 12, 2012, and the purchase of shares on April 13, 2012.
- Transaction Date: April 13, 2012
- Share Price: 1,402 pence per share
- Shares Acquired: 213 Ordinary Shares
- Related Director/PDMR: Dr. P. J. T. Vallance
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Verify the total shareholding of Dr. S. Dexter post-transaction to assess concentration of ownership.
- Confirm the dividend reinvestment plan terms applicable to the April 12, 2012 payment.
- Note that this filing does not contain quarterly or annual financial performance data.